Tadalafil 5 mg Once Daily Improves Lower Urinary Tract Symptoms and Erectile Dysfunction: A Systematic Review and Meta‐analysis

@article{Wang2018Tadalafil5M,
  title={Tadalafil 5 mg Once Daily Improves Lower Urinary Tract Symptoms and Erectile Dysfunction: A Systematic Review and Meta‐analysis},
  author={Yilin Wang and Yiping Bao and Jie Liu and Lijun Duan and Yuanshan Cui},
  journal={LUTS: Lower Urinary Tract Symptoms},
  year={2018},
  volume={10}
}
We carried out a systematic review and meta‐analysis to assess tadalafil 5 mg once‐daily for the treatment of lower urinary tract symptoms (LUTS) and erectile dysfunction (ED). 
Lower urinary tract symptoms: initial management in men
Lower urinary tract symptoms are common in the ageing male and can significantly impact upon quality of life. This article discusses the symptoms commonly experienced, investigations and initialExpand
Add‐on effects of tadalafil in tamsulosin‐treated patients with small benign prostatic enlargement: A randomized, placebo‐controlled, double‐blind, crossover study
TLDR
To assess the add‐on effects of tadalafil in patients with a relatively small benign prostatic enlargement treated with tamsulosin, a large number of patients with small BPEs are treated with this drug. Expand
Erectile Dysfunction and Lower Urinary Tract Symptoms
TLDR
The role of phosphodiesterase inhibitors alone or in combination with alpha blockers to treat LUTS and ED, especially in younger patients, is strongly supported by high level of evidence. Expand
Lower Urinary Tract Symptoms and Sexual Dysfunction in Male: A Systematic Review and Meta-Analysis
TLDR
In a detailed analysis of specific sexual function domains, the severity of LUTS was associated with erectile dysfunction, intercourse satisfaction, and overall satisfaction, except for sexual desire. Expand
Phosphodiesterase type 5 inhibitors in treatment of lower urinary tract dysfunctions
TLDR
The mechanisms of the therapeutic action of these drugs for various urinary tract dysfunctions are examined in detail, the leading of which is the improvement of blood circulation and the reduction of ischemia of the pelvic organs. Expand
Impact of low‐dose tadalafil on adverse events after low‐dose‐rate brachytherapy for prostate cancer: A bi‐center randomized open‐label trial
To study the efficacy of phosphodiesterase‐5 inhibitor tadalafil in attenuating adverse events after low‐dose‐rate brachytherapy for prostate cancer.
The safety and efficacy of PDE5-inhibitors-vardenafil on treating diabetes mellitus erectile dysfunction
TLDR
A systematic review and meta-analysis of the effectiveness, recurrence rate, and symptom scores of Diabetic mellitus erectile dysfunction using PDE5-inhibitors-vardenafil and related randomized controlled trials included in the China Resources Database is conducted. Expand
Efficacy of a combination of dutasteride, tadalafil, and solifenacin in the treatment of previously unsuccessful patients
TLDR
The simultaneous administration of standard doses of dutasteride, solifenacin and tadalafil for 3 months is safe, effective and can be recommended for patients with BPH to reduce symptoms of obstruction and hyperactivity of the bladder and maintain sexual function. Expand
Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia
TLDR
The purpose of this review is to provide current comprehensive perspectives on the mechanisms of action, efficacy, and adverse reactions associated with the drugs most commonly used for the treatment of BPH. Expand
Is Early Surgical Treatment for Benign Prostatic Hyperplasia Preferable to Prolonged Medical Therapy: Pros and Cons
TLDR
Randomized clinical trials comparing the outcomes for prolonged medical therapy versus early surgical treatment could determine which approach is more beneficial in the long-term in context of the aging population. Expand
...
1
2
...

References

SHOWING 1-10 OF 52 REFERENCES
Tadalafil 5 mg once‐daily therapy for men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: Results from a randomized, double‐blind, placebo‐controlled trial carried out in Japan and Korea
TLDR
To gain further evidence on the efficacy, safety and tolerability of tadalafil 5 mg once‐daily in Asian men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia, a large number of men were referred for treatment with this drug. Expand
Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men
To examine the efficacy and safety of tadalafil in Asian men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Pathophysiology and mechanism(s) of action
TLDR
This manuscript reviews the published literature describing the pathophysiology of male LUTS, with an emphasis on mechanisms that may be modulated or improved by phosphodiesterase type 5 (PDE5) inhibition. Expand
Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction
TLDR
This study examined whether once‐daily tadalafil 2.5 and 5 mg is efficacious for men with diabetes and ED. Expand
Tadalafil in the treatment of erectile dysfunction
TLDR
The pharmacokinetic and pharmacodynamic characteristics, efficacy, and safety of tadalafil, the preferred first-line treatment for erectile dysfunction, are discussed. Expand
The relationship between erectile dysfunction and lower urinary tract symptoms: Epidemiological, clinical, and basic science evidence
TLDR
The link between ED and LUTS has biologic plausibility given the four leading theories of how these diseases inter-relate and is supported by the consistent linear relationship of more severe LUTs with more severe ED. Expand
The relationship between erectile dysfunction and lower urinary tract symptoms: Epidemiological, clinical, and basic science evidence
TLDR
The link between ED and LUTS has biologic plausibility given the four leading theories of how these diseases inter-relate and is supported by the consistent linear relationship of more severe LUTs with more severe ED. Expand
A placebo‐controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK‐369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia
TLDR
Study Type – Therapy (RCT)’s level of evidence’1b, and “Level of Evidence 1b” indicate that RCTs are more likely to provide positive results than placebo-controlled trials. Expand
Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia.
TLDR
These data support the use of once-daily tadalafil in men with ED and BPH-LUTS and no significant differences between subgroup or subgroup-by-treatment interaction terms are observed. Expand
Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
TLDR
Once daily tadalafil demonstrated clinically meaningful and statistically significant efficacy and it was well tolerated in men with benign prostatic hyperplasia lower urinary tract symptoms. Expand
...
1
2
3
4
5
...